Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 10Unknown 8Recruiting 8Withdrawn 1Terminated 1Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 25Lymphoma, Large B-Cell, Diffuse 16Lymphoma 15Burkitt Lymphoma 11Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell 7Hodgkin Disease 6Lymphoma, Non-Hodgkin 5Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Melanoma 2Lymphoproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, AIDS-Related 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Immunoblastic Lymphadenopathy 2Vasculitis, Central Nervous System 1Urogenital Neoplasms 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Skin Neoplasms 1Rasmussen subacute encephalitis 1Prostate Cancer, Hereditary, 7 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2romidepsin 1decitabine and cedazuridine drug combination 1Vincristine 1Tomography, X-Ray Computed 1Prednisone 1Oxaliplatin 1Gemcitabine 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1ASTX-660 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, T-Cell, Peripheral × Prednisone × Clear all
NCT02223208 2025-12-02

FIL_PTCL13

Fondazione Italiana Linfomi - ETS

Phase 1/2 Active not recruiting
89 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡